2nd Annual Ma Day Feedback Note
Upcoming SlideShare
Loading in...5
×
 

2nd Annual Ma Day Feedback Note

on

  • 410 views

The 2nd annual Market Access Day organized by EMAUD gathered over a hundred industry healthcare professionals. The event was an enriching meeting with a high level of interaction & discussion.

The 2nd annual Market Access Day organized by EMAUD gathered over a hundred industry healthcare professionals. The event was an enriching meeting with a high level of interaction & discussion.

Statistics

Views

Total Views
410
Views on SlideShare
398
Embed Views
12

Actions

Likes
0
Downloads
0
Comments
0

2 Embeds 12

http://www.linkedin.com 10
https://www.linkedin.com 2

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

2nd Annual Ma Day Feedback Note 2nd Annual Ma Day Feedback Note Presentation Transcript

  • 2nd Annual Market Access Day Pricing of Pharmaceuticals:Is There A Universal Foundation To Set A Fair Price? 3 December 2010 - Paris, Ecole du Val de Grâce In the context of the current economic crisis and increasing budget constraints for healthcare expenditure, pricing of pharmaceuticals has become an even more sensitive subject than usual. For this reason, for the second annual Market Access Day in Paris, EMAUD gathered experts from North America and Europe who contributed their viewpoints on the concept of fair pricing, answering the question: “Pricing of pharmaceuticals: is there a universal foundation to set a fair price?” Over a hundred healthcare industry professionals attended and the event was an enriching meeting with a high level of interaction and discussion. Representatives from G-BA, NICE, EMA, EFPIA, Andalusia, Catsalut, and INSERM, attended, as well as professors from the universities of Pittsburg, McMaster, Twente, and Tufts. Speakers evaluated the performance of the pricing systems currently in place and explored what could be the answer to setting a ‘fair price’ for pharmaceuticals. Many felt that although all reforms aim at aligning value and price, affordability has become a key element of market access. It is therefore difficult to draw specific lessons applicable to all markets and to supply a single answer to define what fair pricing is; however, many countries are currently trying to integrate objective affordability limits in their pricing practices. www.emaud.org